MARKET

ORKA

ORKA

Oruka Therapeutics Inc
NASDAQ
84.46
-1.03
-1.20%
After Hours: 84.46 0 0.00% 19:30 09/25 EDT
OPEN
86.49
PREV CLOSE
85.49
HIGH
86.49
LOW
84.00
VOLUME
499.72K
TURNOVER
--
52 WEEK HIGH
115.52
52 WEEK LOW
14.89
MARKET CAP
5.59B
P/E (TTM)
-34.3180
1D
5D
1M
3M
1Y
5Y
1D
ORKA-002 Trial Progress: What Oruka’s New HS Study Means for Investors
TipRanks · 2d ago
Oruka Therapeutics Price Target Maintained With a $165.00/Share by Wedbush
Dow Jones · 2d ago
Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target
Benzinga · 2d ago
Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA) and Co-Diagnostics (CODX)
TipRanks · 2d ago
Oruka Therapeutics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Oruka Therapeutics (ORKA) and Harmony Biosciences Holdings (HRMY)
TipRanks · 2d ago
Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Oruka Therapeutics (ORKA)
TipRanks · 3d ago
Oruka falls after updating mid-stage trial data for plaque psoriasis therapy
Seeking Alpha · 3d ago
More
About ORKA
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

Webull offers Oruka Therapeutics Inc stock information, including NASDAQ: ORKA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORKA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORKA stock methods without spending real money on the virtual paper trading platform.